Imatinib mesylate:MCnc:Pt:Ser/Plas:Qn

Known as: Imatinib mésylate [Masse/Volume] Sérum/Plasma ; Numérique, Imatinib mesylate:Mass Concentration:Point in time:Serum/Plasma:Quantitative, Imatinib mesylate [Mass/volume] in Serum or Plasma 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2012
01220042012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The anticancer drug imatinib is an inhibitor of the platelet-derived growth factor receptor (PDGFR) kinases, which are involved… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 5
  • figure 4
Is this relevant?
2010
2010
Imatinib, a selective inhibitor of c-KIT and Bcr-Abl tyrosine kinases, approved for the treatment of chronic myelogenous leukemia… (More)
Is this relevant?
2010
2010
Imatinib inhibits Bcr-Abl, c-KIT and PDGFR kinases. It is approved for the treatment of chronic myeloid leukemia (CML… (More)
Is this relevant?
2004
2004
2081 Background: Imatinib (STI-571), approved for treatment of CML & GIST, is administered as daily PO therapy and is primarily… (More)
Is this relevant?